AMRS: Amyris, Inc. - Summary | Jitta

Amyris, Inc.

NASDAQ:AMRS

Notice
Stock data is unavailable or the company’s delisted.
Price
$0.00
Loss Chance
58.4%
0.01JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (32)
Recent Business Performance (22)
Financial Strength (30)
Return to Shareholders (13)
Competitive Advantage (28)
Jitta Signs
Revenue and EarningEarning loss detected in 2022
Operating MarginDeclined
Recent Business PerformanceEarning decline 181.82% in the last year
New Share IssuedMore than 50% in 5 years
CapExVery High
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
0.01
100.00%
3.66
188.71%
3.88
256.12%
Specialty Chemicals
3.57
441.83%
1.55
95.62%
8.18
122.78%
COMPANY DESCRIPTION
Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California. On August 9, 2023, Amyris, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.